Retrovir (AZT) block grants
Executive Summary
The Health Resources and Services Adminstration sends letter to states announcing the availability of $15 mil. to provide AZT for indigent patients. New York is eligible for top amount, $3.9 mil. Each state is eligible for for at least $15,000, and 22 states are eligible for more than $100,000. The funds, $5 mil. of which is being provided by Burroughs Wellcome are intended to extend the fiscal 1988 AZT block grant through the first half of 1989. The letter emphasizes that funding priority is to be given to patients who received AZT under the Treatment IND program....
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.